

# Elevate the standard of cervical cancer screening

HPV extended genotyping is an innovative screening tool to enhance clinical management.

Individual identification of high-risk genotypes is essential to reveal the true risk of CIN3+ disease<sup>\*,1</sup>

## Partial genotyping:

Only 2 high-risk HPV types individually identified



16

18

high risk  
other

## Extended genotyping with BD Onclarity™ HPV Assay:

6 high-risk HPV types individually identified



16

18

45

31

52

51

35  
39  
68

33  
58

56  
59  
66



Individual results




Pooled results

## BD Onclarity™ HPV Assay has officially been added to the ASCCP guidelines

The American Society for Colposcopy and Cervical Pathology (ASCCP) has separated the BD Onclarity™ HPV Assay channels into three different risk-based tiers, which inform new clinical recommendations.<sup>2</sup>

### Patient management with BD Onclarity™ HPV Assay (Co-Testing / HPV Primary)



It's time to redefine screening and make powerful progress towards **eliminating cervical cancer**

Learn more about BD Onclarity™ HPV Assay

\*CIN, cervical intraepithelial neoplasia.

\*Note: Dual Stain is not FDA approved for use as a triage with BD Onclarity™ HPV Assay

#### References:

1. Bonde JH et al. *J Low Genit Tract Dis.* 2020;24(1):1–13.
2. ASCCP. Management Guidelines and the Enduring Guidelines Process. Accessed February 2025.

**bd.com**

BD, the BD logo, and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates.  
All other trademarks are the property of their respective owners. ©2025 BD. All rights reserved. (BD-145682 3975-US-0325 March 2025)

